At the conference, An Youcai, the Chairman and General Manager of the company, was invited to participate in the roundtable forum titled "New Productivity Engine: How AI Reshapes the Value Growth Curve of Hong Kong Stock Exchange Listed Companies". He shared the latest developments in his field with numerous industry experts, breaking down industry barriers and engaging in cutting-edge intellectual exchanges and experience sharing regarding the application of AI technology and scientific empowerment in the full-chain operation of research, production, and sales of Zhonghui Biotech.

After the meeting, Mr. An gave an exclusive interview to a reporter from China Securities Journal. Focusing on Ab&B Bio's market performance and future development strategies after its listing on the Hong Kong Stock Exchange, he discussed the core logic behind Ab&B Bio's high market recognition after its listing. He also elaborated on how the company plans to embrace the wave of change, with innovation-driven, quality leadership, management efficiency improvement, and overseas expansion as its strategic axes, striving towards the vision of enabling China to use globally innovative vaccines and the world to use high-quality Chinese vaccines!

Ab&B Bio-Tech Co.,Ltd (Ab&B Bio) is committed to the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines utilizing new technological methods. Aiming at international standards, it conducts independent and innovative research and development. To date, it has obtained multiple clinical trial approvals for new drugs and is orderly conducting clinical trials and NDA submissions.
Ab&B Bio's founding principle is to avoid mere replication, align with global trends, and develop innovative vaccines. Its mission is to cherish life and safeguard health! Ab&B Bio will uphold the spirit of innovation, pragmatism, self-discipline, integrity, and perseverance, striving to make global innovative vaccines accessible in China and high-quality Chinese vaccines available to the world!

Yither Bio, established in 2020, is a wholly-owned subsidiary of Ab&B Bio. Since its inception, it has adhered to the principle of not simply replicating its parent company's projects, and has been committed to building an innovative R&D team with an international perspective and world-class capabilities, dedicated to the research, development, and industrialization of innovative vaccines for human use.
To date, the company has established multiple technical platforms, including recombinant genetic engineering vaccine research platform, mRNA vaccine research platform, polysaccharide conjugate vaccine research platform, and innovative adjuvant research platform. It has also swiftly advanced the research, development, and production of various pipelines, such as multivalent pneumococcal conjugate vaccines, recombinant shingles vaccines, recombinant respiratory syncytial virus vaccines, and mRNA poxvirus vaccines.